ArticleHeadache
Can serum neuropeptide levels help diagnose pediatric migraine? A prospective case-control study.
Article in Headache. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Migraine in pediatric population: the role of biochemical markers.The journal of headache and pain · 2026Pooled it
- Children's Headache Through Drawings: A Narrative Review and a Portrait Gallery.Life (Basel, Switzerland) · 2025Review
- A Review of the Biochemical Diagnostic Biomarkers in Migraine: New Perspectives in Diagnostics.Pain research & management · 2025Review
- Can serum neuropeptide levels help diagnose pediatric migraine? A prospective case-control study.HeadacheArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThe objective of this study was to examine the serum levels of vasoactive neuropeptides (calcitonin gene-related peptide [CGRP], pituitary adenylate cyclase-activating peptide-38 [PACAP-38], substance P [SP], and vasoactive intestinal peptide [VIP], which have been linked to the pathophysiology of migraine in adults) in pediatric migraine without aura during both pain attacks and pain-free periods and in a control group, with a view of evaluating their diagnostic value in pediatric migraine.
backgroundThe diagnosis of migraine is based on clinical features described by patients and pediatric patients may not be able to express migraine symptoms as clearly as adults. The fact that objective biological markers of migraine have not yet been fully defined makes diagnosis difficult, especially in children.
methodsThis prospective cross-sectional case-control study included 39 children and adolescents (aged 8-18 years) diagnosed with migraine without aura and 40 healthy control children between May 2022 and March 2023. The 39 patients with migraine were evaluated both during the course of their migraine attacks and during periods of pain-free status. Plasma vasoactive peptides were measured using an enzyme-linked immunosorbent assay.
resultsThe comparison of serum SP, PACAP-38, and CGRP neuropeptide levels in the 39 patients with migriane during the ictal and interictal periods revealed no significant differences between the two periods. VIP neuropeptide levels in the ictal period (mean [standard deviation, SD] 291.6 [118.5] pg/mL) in the migraine cohort were found to be significantly higher than the levels observed in both the interictal (mean [SD] 263.6 [100.9] pg/mL, p = 0.019) and healthy control groups (mean [SD] 229.7 [109.3] pg/mL, p = 0.018) (p < 0.05). The level of the neuropeptide SP (mean [SD] 150.5 [29] pg/mL) in the interictal period was found to be lower than that observed in the healthy control group (mean [SD] 174.6 [39.4] pg/mL, p = 0.030) (p < 0.05). Furthermore, the CGRP level in the interictal period (mean [SD] 395.6 [197.6] pg/mL) was found to be significantly higher than that observed in the healthy control group (mean [SD] 320.3 [126.6] pg/mL, p = 0.049) (p < 0.05). No significant differences were observed in the levels of the other neuropeptides.
conclusionsThe present study revealed elevated VIP levels during the ictal period and elevated CGRP levels during the interictal period in patients with migraine without aura when compared to controls. In addition, VIP serum levels were significantly higher in the ictal period compared to both the interictal period and healthy controls. The findings of our study lend support to the use of these neuropeptides as biomarkers for migraine. Nevertheless, further studies and standardization are necessary to ascertain the diagnostic value of single or combinations of SP, PACAP-38, VIP, and CGRP neuropeptides in diagnosing pediatric migraine and differentiating pediatric migraine from non-migraine headaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.